| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Hypoglycemic Agents | 27 | 2021 | 2165 | 3.67 | Why? |
| Diabetes Mellitus, Type 2 | 36 | 2020 | 6166 | 3.43 | Why? |
| Dipeptidyl-Peptidase IV Inhibitors | 10 | 2021 | 436 | 3.04 | Why? |
| Benzhydryl Compounds | 9 | 2018 | 240 | 2.23 | Why? |
| Glucosides | 9 | 2018 | 359 | 2.04 | Why? |
| Diabetic Angiopathies | 5 | 2019 | 146 | 1.76 | Why? |
| Sodium-Glucose Transporter 2 | 10 | 2019 | 111 | 1.65 | Why? |
| Diabetes Mellitus, Type 1 | 16 | 2021 | 1969 | 1.57 | Why? |
| Stem Cells | 5 | 2018 | 595 | 1.20 | Why? |
| Insulin | 12 | 2019 | 1316 | 1.09 | Why? |
| Hypoglycemia | 8 | 2021 | 406 | 1.08 | Why? |
| Blood Glucose | 22 | 2021 | 3642 | 0.95 | Why? |
| Glucagon-Like Peptide-1 Receptor | 3 | 2019 | 138 | 0.93 | Why? |
| Src Homology 2 Domain-Containing, Transforming Protein 1 | 2 | 2018 | 11 | 0.92 | Why? |
| Chemokine CXCL12 | 2 | 2018 | 74 | 0.90 | Why? |
| Endothelial Progenitor Cells | 2 | 2018 | 103 | 0.82 | Why? |
| Basal Metabolism | 1 | 2019 | 47 | 0.79 | Why? |
| Caloric Restriction | 1 | 2019 | 56 | 0.77 | Why? |
| Reproductive Tract Infections | 1 | 2017 | 45 | 0.70 | Why? |
| 3-Hydroxybutyric Acid | 1 | 2017 | 16 | 0.70 | Why? |
| Diabetic Cardiomyopathies | 1 | 2018 | 79 | 0.66 | Why? |
| Canagliflozin | 1 | 2017 | 56 | 0.66 | Why? |
| Metformin | 3 | 2019 | 640 | 0.65 | Why? |
| Leptin | 1 | 2018 | 141 | 0.64 | Why? |
| Linagliptin | 1 | 2015 | 22 | 0.63 | Why? |
| Hyperglycemia | 5 | 2021 | 1363 | 0.61 | Why? |
| Neovascularization, Pathologic | 1 | 2019 | 305 | 0.60 | Why? |
| Energy Metabolism | 1 | 2019 | 451 | 0.57 | Why? |
| Amputation | 1 | 2017 | 331 | 0.56 | Why? |
| Dipeptidyl Peptidase 4 | 3 | 2021 | 1061 | 0.56 | Why? |
| Heart Failure | 5 | 2019 | 6638 | 0.55 | Why? |
| Coronary Disease | 2 | 2017 | 645 | 0.53 | Why? |
| Cholesterol, HDL | 1 | 2017 | 439 | 0.52 | Why? |
| Cardiovascular Diseases | 9 | 2019 | 11497 | 0.52 | Why? |
| Diabetic Ketoacidosis | 2 | 2017 | 622 | 0.48 | Why? |
| Adipose Tissue | 1 | 2017 | 612 | 0.46 | Why? |
| Diabetes Mellitus | 4 | 2021 | 8207 | 0.44 | Why? |
| Cardiovascular System | 2 | 2019 | 750 | 0.43 | Why? |
| Diabetes Complications | 3 | 2020 | 2358 | 0.43 | Why? |
| Stroke Volume | 2 | 2018 | 2153 | 0.43 | Why? |
| Exercise Therapy | 1 | 2019 | 976 | 0.41 | Why? |
| Glycated Hemoglobin A | 10 | 2019 | 1316 | 0.41 | Why? |
| Pharmacovigilance | 3 | 2019 | 501 | 0.39 | Why? |
| Monocytes | 3 | 2017 | 2978 | 0.39 | Why? |
| Leukocytes, Mononuclear | 1 | 2018 | 2115 | 0.35 | Why? |
| Evidence-Based Medicine | 2 | 2018 | 3228 | 0.34 | Why? |
| Insulin Infusion Systems | 3 | 2021 | 256 | 0.33 | Why? |
| Coronary Angiography | 1 | 2017 | 2275 | 0.33 | Why? |
| Diabetic Nephropathies | 3 | 2018 | 315 | 0.30 | Why? |
| Blood Glucose Self-Monitoring | 4 | 2021 | 791 | 0.30 | Why? |
| Diabetic Neuropathies | 2 | 2017 | 64 | 0.28 | Why? |
| Carotid Artery Diseases | 2 | 2018 | 251 | 0.28 | Why? |
| Glucocorticoids | 1 | 2020 | 4431 | 0.28 | Why? |
| Plaque, Atherosclerotic | 3 | 2018 | 423 | 0.27 | Why? |
| Obesity | 3 | 2019 | 7388 | 0.26 | Why? |
| Body Weight | 3 | 2019 | 1074 | 0.26 | Why? |
| Antigens, CD34 | 3 | 2018 | 125 | 0.26 | Why? |
| Italy | 15 | 2021 | 38444 | 0.25 | Why? |
| Point-of-Care Systems | 1 | 2017 | 2955 | 0.25 | Why? |
| Diabetic Retinopathy | 2 | 2018 | 347 | 0.24 | Why? |
| Fasting | 2 | 2017 | 555 | 0.22 | Why? |
| Practice Patterns, Physicians' | 2 | 2019 | 4927 | 0.22 | Why? |
| Diabetic Foot | 2 | 2018 | 317 | 0.22 | Why? |
| Humans | 64 | 2021 | 930598 | 0.21 | Why? |
| Fatty Acids, Nonesterified | 3 | 2017 | 60 | 0.21 | Why? |
| Fournier Gangrene | 1 | 2019 | 19 | 0.20 | Why? |
| Drug-Related Side Effects and Adverse Reactions | 3 | 2019 | 1261 | 0.20 | Why? |
| Diet, Reducing | 1 | 2019 | 38 | 0.20 | Why? |
| Sodium Potassium Chloride Symporter Inhibitors | 1 | 2019 | 49 | 0.20 | Why? |
| Urogenital System | 1 | 2019 | 49 | 0.20 | Why? |
| Glucagon | 2 | 2018 | 52 | 0.19 | Why? |
| Phenotype | 4 | 2018 | 4037 | 0.19 | Why? |
| Neuropeptide Y | 1 | 2018 | 14 | 0.19 | Why? |
| Male | 43 | 2021 | 367725 | 0.19 | Why? |
| Female | 42 | 2021 | 380317 | 0.18 | Why? |
| Diabetic Coma | 1 | 2017 | 1 | 0.18 | Why? |
| Case-Control Studies | 9 | 2020 | 17671 | 0.18 | Why? |
| Receptors, CXCR4 | 1 | 2018 | 83 | 0.18 | Why? |
| Cholesterol, LDL | 2 | 2019 | 499 | 0.18 | Why? |
| Membrane Transport Modulators | 1 | 2017 | 11 | 0.18 | Why? |
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2018 | 66 | 0.18 | Why? |
| Glucagon-Like Peptide 1 | 1 | 2018 | 83 | 0.18 | Why? |
| Pregnancy in Diabetics | 1 | 2018 | 56 | 0.18 | Why? |
| Growth Hormone-Secreting Pituitary Adenoma | 1 | 2017 | 12 | 0.18 | Why? |
| Acetoacetates | 1 | 2017 | 3 | 0.18 | Why? |
| Diagnostic Techniques, Endocrine | 1 | 2017 | 12 | 0.18 | Why? |
| Insulin Glargine | 1 | 2017 | 43 | 0.17 | Why? |
| Hyperinsulinism | 1 | 2017 | 27 | 0.17 | Why? |
| Biomarkers | 11 | 2019 | 23361 | 0.17 | Why? |
| Incretins | 1 | 2018 | 61 | 0.17 | Why? |
| Middle Aged | 35 | 2021 | 270681 | 0.17 | Why? |
| Risk Factors | 12 | 2020 | 71621 | 0.17 | Why? |
| Glomerular Filtration Rate | 3 | 2018 | 1262 | 0.17 | Why? |
| Delayed-Action Preparations | 1 | 2019 | 291 | 0.17 | Why? |
| Myocardial Revascularization | 1 | 2019 | 267 | 0.16 | Why? |
| Sulfonylurea Compounds | 1 | 2017 | 79 | 0.16 | Why? |
| Circulating MicroRNA | 1 | 2017 | 123 | 0.16 | Why? |
| Internal-External Control | 1 | 2017 | 65 | 0.16 | Why? |
| Plasminogen Activator Inhibitor 1 | 1 | 2017 | 162 | 0.16 | Why? |
| Cross-Over Studies | 2 | 2017 | 867 | 0.15 | Why? |
| Cognition Disorders | 2 | 2018 | 574 | 0.15 | Why? |
| Gait | 2 | 2017 | 137 | 0.15 | Why? |
| Adrenergic beta-Antagonists | 1 | 2019 | 465 | 0.15 | Why? |
| Aged | 22 | 2021 | 215776 | 0.15 | Why? |
| Disease Progression | 4 | 2018 | 13580 | 0.15 | Why? |
| Flow Cytometry | 3 | 2018 | 2393 | 0.14 | Why? |
| Muscle Strength | 1 | 2017 | 317 | 0.14 | Why? |
| Adenoma | 1 | 2017 | 215 | 0.14 | Why? |
| Proteolysis | 1 | 2018 | 751 | 0.13 | Why? |
| Kidney | 2 | 2018 | 3648 | 0.13 | Why? |
| Cardiotonic Agents | 1 | 2017 | 418 | 0.13 | Why? |
| Crowdsourcing | 1 | 2017 | 258 | 0.13 | Why? |
| Heart Injuries | 1 | 2020 | 608 | 0.13 | Why? |
| Ketone Bodies | 2 | 1992 | 53 | 0.13 | Why? |
| Glyburide | 1 | 1992 | 17 | 0.13 | Why? |
| Diabetes, Gestational | 1 | 2018 | 426 | 0.12 | Why? |
| Delphi Technique | 1 | 2017 | 1257 | 0.12 | Why? |
| Myocardial Ischemia | 1 | 2019 | 781 | 0.12 | Why? |
| Insulin Resistance | 1 | 2018 | 669 | 0.12 | Why? |
| Lower Extremity | 1 | 2017 | 593 | 0.12 | Why? |
| Myeloid Cells | 1 | 2017 | 808 | 0.12 | Why? |
| Particle Size | 1 | 2017 | 1052 | 0.11 | Why? |
| Retrospective Studies | 12 | 2021 | 105322 | 0.11 | Why? |
| Circadian Rhythm | 1 | 2017 | 607 | 0.11 | Why? |
| Incidence | 6 | 2020 | 25622 | 0.11 | Why? |
| Prevalence | 5 | 2020 | 25773 | 0.11 | Why? |
| Natriuretic Peptide, Brain | 1 | 2018 | 1215 | 0.11 | Why? |
| Tissue Plasminogen Activator | 1 | 2017 | 778 | 0.11 | Why? |
| Inflammation | 3 | 2018 | 13255 | 0.11 | Why? |
| Randomized Controlled Trials as Topic | 3 | 2019 | 10649 | 0.11 | Why? |
| Foot | 1 | 2012 | 195 | 0.10 | Why? |
| Long QT Syndrome | 1 | 2020 | 1047 | 0.10 | Why? |
| Drug Interactions | 1 | 2017 | 1653 | 0.10 | Why? |
| United States Food and Drug Administration | 1 | 2017 | 1276 | 0.10 | Why? |
| Drug Therapy, Combination | 3 | 2019 | 7268 | 0.10 | Why? |
| Cognition | 1 | 2018 | 1394 | 0.09 | Why? |
| Extracellular Traps | 1 | 2018 | 1036 | 0.09 | Why? |
| Endothelial Cells | 2 | 2017 | 2048 | 0.09 | Why? |
| Heart | 1 | 2018 | 1791 | 0.09 | Why? |
| Hemorrhage | 1 | 2020 | 3013 | 0.09 | Why? |
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2019 | 1510 | 0.08 | Why? |
| Prognosis | 6 | 2020 | 32490 | 0.08 | Why? |
| Personal Satisfaction | 1 | 2017 | 1243 | 0.08 | Why? |
| Treatment Outcome | 9 | 2021 | 51732 | 0.08 | Why? |
| Blood Coagulation | 1 | 2020 | 2768 | 0.08 | Why? |
| Follow-Up Studies | 4 | 2019 | 17020 | 0.08 | Why? |
| Mass Screening | 2 | 2017 | 8005 | 0.08 | Why? |
| Prospective Studies | 5 | 2018 | 43301 | 0.08 | Why? |
| Animals | 5 | 2019 | 78931 | 0.08 | Why? |
| Imaging, Three-Dimensional | 1 | 2012 | 680 | 0.08 | Why? |
| Adult | 20 | 2021 | 244371 | 0.08 | Why? |
| Life Style | 1 | 2019 | 2708 | 0.08 | Why? |
| Aged, 80 and over | 7 | 2020 | 88759 | 0.08 | Why? |
| Time Factors | 6 | 2018 | 31397 | 0.08 | Why? |
| Myocardium | 1 | 2018 | 2323 | 0.08 | Why? |
| Electrocardiography | 1 | 2020 | 3957 | 0.08 | Why? |
| Kidney Diseases | 1 | 2017 | 1434 | 0.07 | Why? |
| Macrophages | 1 | 2017 | 2784 | 0.07 | Why? |
| Software | 1 | 2017 | 2501 | 0.07 | Why? |
| Longitudinal Studies | 2 | 2018 | 9893 | 0.07 | Why? |
| Azithromycin | 1 | 2020 | 3943 | 0.07 | Why? |
| Pneumonia, Viral | 4 | 2020 | 243684 | 0.07 | Why? |
| Coronavirus Infections | 4 | 2020 | 253789 | 0.07 | Why? |
| Gastrointestinal Microbiome | 1 | 2018 | 1961 | 0.07 | Why? |
| MicroRNAs | 1 | 2017 | 1787 | 0.07 | Why? |
| Inpatients | 1 | 2020 | 5161 | 0.07 | Why? |
| Biomechanical Phenomena | 2 | 2017 | 291 | 0.07 | Why? |
| Patient Admission | 1 | 2020 | 5250 | 0.06 | Why? |
| Chronic Disease | 1 | 2018 | 5139 | 0.06 | Why? |
| Myocardial Infarction | 1 | 2019 | 3361 | 0.06 | Why? |
| Pandemics | 6 | 2021 | 389249 | 0.06 | Why? |
| Angiotensin Receptor Antagonists | 1 | 2019 | 3892 | 0.06 | Why? |
| Computer Simulation | 1 | 2017 | 4982 | 0.06 | Why? |
| Consensus | 1 | 2017 | 6345 | 0.06 | Why? |
| Venous Thromboembolism | 1 | 2020 | 4273 | 0.06 | Why? |
| Fear | 1 | 2017 | 3607 | 0.06 | Why? |
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2019 | 5277 | 0.05 | Why? |
| Renal Insufficiency, Chronic | 1 | 2015 | 2654 | 0.05 | Why? |
| Kidney Failure, Chronic | 1 | 2017 | 3222 | 0.05 | Why? |
| Genital Diseases, Male | 1 | 2019 | 28 | 0.05 | Why? |
| United States | 2 | 2017 | 46150 | 0.05 | Why? |
| Glucagon-Like Peptides | 1 | 2019 | 29 | 0.05 | Why? |
| Hospitalization | 3 | 2020 | 54280 | 0.05 | Why? |
| Liraglutide | 1 | 2019 | 47 | 0.05 | Why? |
| Pancreatitis-Associated Proteins | 1 | 2018 | 5 | 0.05 | Why? |
| Anticoagulants | 1 | 2020 | 9563 | 0.05 | Why? |
| Insulin, Long-Acting | 1 | 2018 | 30 | 0.05 | Why? |
| Genital Diseases, Female | 1 | 2019 | 110 | 0.05 | Why? |
| Gliclazide | 1 | 2018 | 13 | 0.05 | Why? |
| Carotid Artery Injuries | 1 | 2017 | 19 | 0.05 | Why? |
| Age of Onset | 1 | 2020 | 557 | 0.05 | Why? |
| CD36 Antigens | 1 | 2017 | 44 | 0.04 | Why? |
| Photogrammetry | 1 | 2017 | 26 | 0.04 | Why? |
| Ribonuclease III | 1 | 2017 | 45 | 0.04 | Why? |
| Theta Rhythm | 1 | 2017 | 10 | 0.04 | Why? |
| Osteocalcin | 1 | 2017 | 31 | 0.04 | Why? |
| Thrombosis | 1 | 2020 | 7504 | 0.04 | Why? |
| Glucose Clamp Technique | 1 | 2017 | 39 | 0.04 | Why? |
| Predictive Value of Tests | 3 | 2018 | 9537 | 0.04 | Why? |
| AC133 Antigen | 1 | 2017 | 19 | 0.04 | Why? |
| Clinical Trials as Topic | 1 | 2017 | 7330 | 0.04 | Why? |
| Reaction Time | 1 | 2017 | 96 | 0.04 | Why? |
| Somatostatin | 1 | 2017 | 49 | 0.04 | Why? |
| Telemedicine | 2 | 2021 | 25032 | 0.04 | Why? |
| Caspase 3 | 1 | 2017 | 218 | 0.04 | Why? |
| DEAD-box RNA Helicases | 1 | 2017 | 99 | 0.04 | Why? |
| C-Peptide | 1 | 2017 | 77 | 0.04 | Why? |
| Diet, High-Fat | 1 | 2018 | 161 | 0.04 | Why? |
| Lipoproteins, LDL | 1 | 2017 | 115 | 0.04 | Why? |
| Pelvis | 1 | 2017 | 125 | 0.04 | Why? |
| Comorbidity | 2 | 2020 | 34796 | 0.04 | Why? |
| Mice, Inbred C57BL | 2 | 2018 | 5542 | 0.04 | Why? |
| Diagnostic Techniques, Ophthalmological | 1 | 2018 | 136 | 0.04 | Why? |
| Range of Motion, Articular | 1 | 2017 | 168 | 0.04 | Why? |
| THP-1 Cells | 1 | 2017 | 374 | 0.04 | Why? |
| Joints | 1 | 2017 | 97 | 0.04 | Why? |
| Psychomotor Performance | 1 | 2017 | 110 | 0.04 | Why? |
| Equipment Design | 2 | 2018 | 3095 | 0.04 | Why? |
| Carotid Intima-Media Thickness | 1 | 2017 | 179 | 0.04 | Why? |
| Carotid Arteries | 1 | 2018 | 182 | 0.04 | Why? |
| GPI-Linked Proteins | 1 | 2017 | 317 | 0.04 | Why? |
| Alkaline Phosphatase | 1 | 2017 | 257 | 0.04 | Why? |
| Hospital Mortality | 1 | 2020 | 22087 | 0.04 | Why? |
| Neovascularization, Physiologic | 1 | 2017 | 160 | 0.04 | Why? |
| Hydroxychloroquine | 1 | 2020 | 12447 | 0.04 | Why? |
| Glucose Tolerance Test | 1 | 2017 | 238 | 0.04 | Why? |
| Gene Deletion | 1 | 2018 | 430 | 0.04 | Why? |
| Cell Separation | 1 | 2017 | 270 | 0.04 | Why? |
| Human Growth Hormone | 1 | 2017 | 120 | 0.04 | Why? |
| Electromyography | 1 | 2017 | 278 | 0.04 | Why? |
| Autonomic Nervous System | 1 | 2017 | 148 | 0.04 | Why? |
| Antineoplastic Agents, Hormonal | 1 | 2017 | 203 | 0.04 | Why? |
| Young Adult | 7 | 2021 | 93724 | 0.04 | Why? |
| Epinephrine | 1 | 2017 | 323 | 0.04 | Why? |
| Death, Sudden, Cardiac | 1 | 2020 | 522 | 0.04 | Why? |
| Lipopolysaccharide Receptors | 1 | 2017 | 357 | 0.04 | Why? |
| Asymptomatic Diseases | 2 | 2018 | 3444 | 0.04 | Why? |
| Insulin-Secreting Cells | 1 | 2017 | 273 | 0.03 | Why? |
| Calcinosis | 1 | 2017 | 240 | 0.03 | Why? |
| Receptors, IgG | 1 | 2017 | 578 | 0.03 | Why? |
| Practice Guidelines as Topic | 1 | 2018 | 15421 | 0.03 | Why? |
| Quarantine | 1 | 2021 | 18418 | 0.03 | Why? |
| Awareness | 1 | 2018 | 529 | 0.03 | Why? |
| Homeostasis | 1 | 2017 | 582 | 0.03 | Why? |
| Neuropsychological Tests | 1 | 2018 | 954 | 0.03 | Why? |
| Cross-Sectional Studies | 5 | 2018 | 53120 | 0.03 | Why? |
| China | 1 | 2020 | 50654 | 0.03 | Why? |
| Disease-Free Survival | 1 | 2017 | 1654 | 0.03 | Why? |
| Interleukin-1beta | 1 | 2017 | 992 | 0.03 | Why? |
| Stress, Mechanical | 1 | 2012 | 143 | 0.03 | Why? |
| Drug Monitoring | 1 | 2020 | 1408 | 0.03 | Why? |
| Disease Outbreaks | 1 | 2020 | 27595 | 0.03 | Why? |
| Healthy Volunteers | 1 | 2017 | 1444 | 0.03 | Why? |
| Reproducibility of Results | 2 | 2018 | 11304 | 0.03 | Why? |
| Data Mining | 1 | 2017 | 767 | 0.03 | Why? |
| Models, Anatomic | 1 | 2012 | 191 | 0.03 | Why? |
| Diagnostic Errors | 1 | 2017 | 865 | 0.03 | Why? |
| Pressure | 1 | 2012 | 289 | 0.03 | Why? |
| Electroencephalography | 1 | 2017 | 1242 | 0.03 | Why? |
| Reference Values | 1 | 2012 | 795 | 0.02 | Why? |
| Betacoronavirus | 4 | 2020 | 204454 | 0.02 | Why? |
| Africa | 1 | 2018 | 2986 | 0.02 | Why? |
| Analysis of Variance | 1 | 2012 | 950 | 0.02 | Why? |
| Self Care | 1 | 2017 | 918 | 0.02 | Why? |
| Recurrence | 1 | 2018 | 3675 | 0.02 | Why? |
| Leukocyte Count | 1 | 2017 | 3178 | 0.02 | Why? |
| Apoptosis | 1 | 2017 | 2335 | 0.02 | Why? |
| Cells, Cultured | 1 | 2018 | 5835 | 0.02 | Why? |
| Severity of Illness Index | 3 | 2020 | 48226 | 0.02 | Why? |
| Blood Pressure | 1 | 2018 | 2198 | 0.02 | Why? |
| Clinical Decision-Making | 1 | 2020 | 3755 | 0.02 | Why? |
| Linear Models | 1 | 1992 | 1914 | 0.02 | Why? |
| Patient Safety | 1 | 2020 | 4885 | 0.02 | Why? |
| Liver Circulation | 1 | 1984 | 12 | 0.02 | Why? |
| Gluconeogenesis | 1 | 1984 | 41 | 0.02 | Why? |
| Cause of Death | 1 | 2019 | 4823 | 0.02 | Why? |
| Pregnancy Outcome | 1 | 2018 | 3803 | 0.02 | Why? |
| Proportional Hazards Models | 1 | 2017 | 6543 | 0.02 | Why? |
| Risk Assessment | 2 | 2020 | 25439 | 0.02 | Why? |
| Carbohydrate Metabolism | 1 | 1984 | 44 | 0.02 | Why? |
| Radiography | 1 | 2012 | 1576 | 0.02 | Why? |
| Cohort Studies | 2 | 2018 | 36005 | 0.02 | Why? |
| Adolescent | 3 | 2018 | 86841 | 0.02 | Why? |
| Mortality | 1 | 2019 | 7132 | 0.01 | Why? |
| Ultrasonography | 1 | 2018 | 4409 | 0.01 | Why? |
| Neutrophils | 1 | 2018 | 5476 | 0.01 | Why? |
| Double-Blind Method | 1 | 1992 | 5988 | 0.01 | Why? |
| Research Design | 1 | 2017 | 5830 | 0.01 | Why? |
| Algorithms | 1 | 2017 | 7346 | 0.01 | Why? |
| Models, Biological | 1 | 2017 | 4907 | 0.01 | Why? |
| Spain | 1 | 2018 | 15545 | 0.01 | Why? |
| Disease Models, Animal | 1 | 2017 | 10998 | 0.01 | Why? |
| Mice | 1 | 2018 | 21357 | 0.01 | Why? |
| Registries | 1 | 2017 | 12327 | 0.01 | Why? |
| Infant, Newborn | 1 | 2018 | 23105 | 0.01 | Why? |
| Sensitivity and Specificity | 1 | 2017 | 22971 | 0.01 | Why? |
| Pregnancy | 1 | 2018 | 23879 | 0.01 | Why? |
| Liver Cirrhosis | 1 | 1984 | 1810 | 0.01 | Why? |
| Liver | 1 | 1984 | 4007 | 0.01 | Why? |
| Antiviral Agents | 1 | 2020 | 41703 | 0.01 | Why? |
| Portasystemic Shunt, Surgical | 1 | 1984 | 6 | 0.00 | Why? |
| Metabolic Clearance Rate | 1 | 1984 | 110 | 0.00 | Why? |
| Leg | 1 | 1984 | 142 | 0.00 | Why? |
| Triglycerides | 1 | 1984 | 478 | 0.00 | Why? |